PT  - JOURNAL ARTICLE
ED  - ,
TI  - ▼ Sacubitril valsartan for heart failure
AID  - 10.1136/dtb.2016.6.0405
DP  - 2016 Jun 01
TA  - Drug and Therapeutics Bulletin
PG  - 66--69
VI  - 54
IP  - 6
4099  - http://dtb.bmj.com/content/54/6/66.short
4100  - http://dtb.bmj.com/content/54/6/66.full
SO  - Drug Ther Bull2016 Jun 01; 54
AB  - ▼ Sacubitril valsartan (Entresto—Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.1 It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.1-3 Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.